COVID-19 Treatment Algorithm (subject to change)

Admitted with COVID-19

Screen for Gilead RCT eligibility

Inclusion criteria:
- Fever ≥ 36.6 °C axillary, ≥ 37.2 °C oral, or ≥ 37.8 °C rectal
- CXR or CT with pulmonary infiltrates

Assess oxygen requirement

SpO2 ≤ 94% on RA
- Exclusion Criteria (severe disease RCT):
  - Enrolled in any other clinical trial for COVID-19
  - Received agent that could have direct acting antiviral activity against SARS-CoV-2 in last 24h (just hold)
  - Evidence of multiorgan failure
  - ALT / AST > 5x ULN
  - CrCl < 50 mL/min

Note: as of 3/26 intubation is no longer an exclusion criteria

SpO2 > 94% on RA
- Exclusion Criteria (moderate disease RCT):
  - Enrolled in any other clinical trial for COVID-19
  - Received agent that could have direct acting antiviral activity against SARS-CoV-2 in last 24h (just hold)
  - Mechanical ventilation
  - ALT / AST > 5x ULN
  - CrCl < 50 mL/min

Eligible -> Enroll in severe disease trial, randomize 1:1 to 1) Remdesivir 5 days 2) Remdesivir 10 days 3) Standard of Care

Ineligible

Screen for Expanded Access Remdesivir (https://rdvcu.gilead.com/)

Remdesivir Expanded Access is currently in development.

Currently, compassionate use is available only to pregnant women and patients 17 years and younger.

Eligible

Consider enrolling in Gilead Remdesivir Expanded Access

Ineligible

Supportive Care
Experimental treatments may be considered after discussion of risks and unknown benefit with patient.
(see http://med.stanford.edu/id/covid19.html for more information)